Sign in
WithdrawnEarly phase 1

Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Key facts

Who runs it
City of Hope Medical Center
Where
Duarte, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Early phase 1
Started
6 Jul 2024
Ended
31 Oct 2025
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cannabidiol
  • Delta-8-Tetrahydrocannabinol
  • Placebo Administration
  • Questionnaire Administration
Record updated
9 August 2024
Why it stopped
withdrawn

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Documented informed consent of the participant and/or legally authorized representative; Assent, when appropriate, will be obtained per institutional guidelines
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies; If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Willingness to comply with all study interventions including the use of medical cannabis and follow-up assessments
  • Age: >= 18 years
  • Eastern Cooperative Oncology Group (ECOG) =< 2
  • Ability to read and understand English for questionnaires
  • Patients must have either neuropathy >= 1 according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 scale or a neuropathy score of > 3 on a 0-10 scale plus a FACT/GOG-Ntx score of > 10
  • The patient's previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease)
  • Aspartate aminotransferase (AST) =< 3 x ULN
  • Alanine aminotransferase (ALT) =< 3 x ULN
  • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 months after the last dose of protocol therapy; Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
  • Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period. Note: Hormonal therapy is allowed

Who cannot take part

  • Concurrent use of other alternative medicines such as medical cannabis, herbal agents and high dose vitamins and minerals
  • Previous medical cannabis use for any indication within 30 days of enrollment
  • Planned or actual changes in type of medications that could affect symptoms related to CIPN. New medications for the treatment of CIPN are not allowed during the study; Note: Subjects need to be on stable doses of CIPN medications for 4 weeks
  • Strong inhibitors or inducers of CYP3A4
  • Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry (These patients may not be able to cooperate with this slightly invasive procedure or with the data collection process)
  • History of diabetic neuropathy, neuropathy related to human immunodeficiency virus (HIV), or other medical causes of chronic neuropathy in the baseline assessment including past medical history, any history of diabetes, alcoholism, and vitamin B deficiency
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
  • Clinically significant uncontrolled illness
  • Diagnosis of Gilbert's disease
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Liver cirrhosis Child-Pugh B or C
  • Females only: Pregnant or breastfeeding
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Where in United States

  • City of Hope Medical CenterDuarte, United States

About the trial

What the trial wants to find out

This clinical trial tests how well phytocannabinoids (cannabidiol [CBD] and tetrahydrocannbinol [THC]) work in reducing chronic chemotherapy-induced peripheral neuropathy (CIPN) in breast and colon cancer survivors. Neuropathy is the most common neurological symptom reported by cancer patients due to treatment. A variety of pharmacologic treatments have been evaluated to alleviate CIPN symptoms; however, no definitive treatment has been found to successfully treat all the symptoms of CIPN. Therefore, investigators continue to seek other possible treatment options including cannabis. Phytocannabinoids may be a particularly useful intervention for cancer patients given the limited effective treatments for CIPN. In addition, cannabis-based medicines have become tremendously popular as both cancer patients and clinicians are seeking therapies with fewer potential risks of dependency and other side effects. This trial is being done to provide cancer patients and clinicians with reliable information to help guide their use of phytocannabinoids to manage the tremendous distress and pain experienced by many cancer patients, which impacts their long-term quality of life.

The 3 groups in the trial

  • Arm I (CBD)Treatment being tested

    Patients receive CBD PO on study.

    Treatment: Cannabidiol and Questionnaire Administration

  • Arm II (CBD + THC)Treatment being tested

    Patients receive CBD PO + THC PO on study.

    Treatment: Cannabidiol, Delta-8-Tetrahydrocannabinol, and Questionnaire Administration

  • Arm III (placebo)Placebo, for comparison

    Patients receive placebo PO on study.

    Treatment: Placebo Administration and Questionnaire Administration

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
Record updated
9 August 2024